UNSPSC 51285309: Furaltadone hydrochloride

This classification denotes an anti-infective agent with the molecular formula C13H16N4O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37Q02H7JT2, chemically known as 2-oxazolidinone, 5-(morpholinomethyl)-3-((5-nitrofurfurylidene)amino)-, monohydrochloride but more generally known as furaltadone hydrochloride, which bears US NIH Compound Identifier 92968. European Medicines Agency schedules Furaltadone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02285MIG.

Most nations schedule furaltadone hydrochloride under HS 29349990. As of Q4 2014, FURALTADONE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. SMILES: C1CC(OC1/C=N/N2CC(OC2=O)CN3CCOCC3)[N+](=O)[O-].CL.

UNSPSC 51285309 Furaltadone hydrochloride, a Commodity code, shows minimal relevant recent activity in state and local procurement. The code nominally identifies a specific pharmaceutical intermediate, yet the recent opportunities tagged to this code diverge substantially from its scope: Seminole County, Florida's IFB for naloxone and drug deactivation systems; the Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription programs; the City of Tampa's IFB for medical and first aid supplies; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products. None of these procurements specifically reference furaltadone hydrochloride or pharmaceutical intermediates as their focus. The mismatch suggests either misclassification in the source data or that furaltadone hydrochloride itself does not generate substantive state and local solicitation volume under this code.

The recent opportunities that are tagged to this code span medical supplies, emergency response consumables, pharmacy benefit management infrastructure, and generic pharmaceutical sourcing across multiple issuing bodies — county health departments, state health commissions, municipal fire departments, and multistate cooperative purchasing alliances — but they do not align with procurement of furaltadone hydrochloride specifically. Without evidence of dedicated state and local solicitations for this compound, the code presents limited pursuit value for vendors in the pharmaceutical intermediate space.